Biocon Biologics gains full gobal rights to biosimilar Adalimumab

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-23 07:00 GMT | Update On 2025-12-23 07:00 GMT

Bengaluru: Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, has announced that it has secured full and exclusive global rights for Hulio (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics(FKB).

Under this new agreement, Biocon Biologics will assume end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities.

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights.

Under the terms of this agreement, Fujifilm Kyowa Kirin Biologics will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to

Fujifilm Kyowa Kirin Biologics for a specified tenure.

Commercial production of biosimilar Adalimumab at Biocon Biologics’ facilities will commence following successful technology transfer and regulatory approvals.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, said, “This agreement with Fujifilm Kyowa Kirin Biologics provides Biocon Biologics the manufacturing rights to biosimilar Adalimumab, granting us end-to-end control over the product. This strategic move enhances flexibility and cost efficiency, reinforcing our commitment to expanding affordable access to high-quality biologics for patients with inflammatory diseases globally.”

Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business. Viatris had previously in-licensed the product from Fujifilm Kyowa Kirin Biologics. Under the earlier arrangement, Fujifilm Kyowa Kirin Biologics manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO.

Adalimumab is one of the three immunology biosimilars in Biocon Biologics’ overall portfolio.

Read also: Biocon Chief Kiran Mazumdar-Shaw wins USC Business Management Award

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Biocon Biologics gains full gobal rights to biosimilar Adalimumab

Similar News

Pill form of Wegovy gets USFDA approval for weight loss

PLI Schemes reduce API import dependence: Govt tells Parliament

CDSCO Flags Popular Pantoprazole, Telmisartan Batches as Spurious in November Alert

GSK Pharma Slapped Rs 38.06 Cr Decree by Bombay Court in Legacy Property Dispute

Roche Lunsumio VELO bags USFDA approval for subcutaneous use in follicular lymphoma

CDSCO Panel Declines to Consider ACME Generics' Phase IV Trial Results for Liothyronine Tablets

Haryana CGST Arrests Pharma Trader Over Rs 21 Cr Tax Evasion